Management Team
TetraLogic Pharmaceuticals has an experienced management team with complementary expertise in research and development, clinical development, commercialization, finance and operations management. Together, the team has significant leadership capabilities for building a successful biopharmaceutical company.
John M. Gill
Founder, President, Chief Executive Officer and Director
Mr. Gill was Chief Operating Officer and a member of the Board of Directors of 3-Dimensional Pharmaceuticals, Inc. (3DP) until May 2003. He joined 3DP in May 2001 as Executive Vice President and Chief Financial Officer. From 1995 to 2001, Mr. Gill was Vice President and Director, Operations and Finance, SmithKline Beecham Research and Development, now GlaxoSmithKline plc where he was a member of the R&D Executive Committee and Chairman of the R&D Operating Committee. From 1985 to 1995 Mr. Gill served as a founding member and partner in SR One, Limited, SmithKline Beecham's Life Sciences Venture Capital Fund. Mr. Gill currently is a Board member of public and private companies and BioAdvance, the Biotechnology Greenhouse of Southeastern Pennsylvania. He graduated from Rutgers University in 1975 with a BA in accounting and economics after having served in the United States Marine Corp.
Mark A. McKinlay, PhD
Founder, Senior Vice President, Research & Development, Chief Scientific Officer
Dr. McKinlay was a founder and Vice President of R&D ViroPharma Corporation, a company focused on the discovery and development of drugs to treat RNA viral infections from 1994 to 2004. From 1985 to 1994, Dr. McKinlay held a variety of drug discovery and development senior director positions in virology and oncology at Sterling Winthrop Pharmaceuticals Research Division. He was a post-doctoral fellow in the Division of Biophysics at the Johns Hopkins School of Public Health from 1978 to 1980 and received his Ph.D. in biology from the Rensselaer Polytechnic Institute during 1978.
David E. Weng, MD, PhD
Chief Medical Officer
Dr. Weng is the Chief Medical Officer for TetraLogic Pharmaceuticals. He began his biotechnology industry career at MedImmune, LLC, and subsequently AstraZeneca. Prior to his industry activities, Dr. Weng was engaged in the practice of medical oncology and cancer research at the Taussig Cancer Center of the Cleveland Clinic Foundation. He is board-certified by the American Board of Internal Medicine in medical oncology, with active state and federal licensing for clinical practice. Dr. Weng graduated from Harvard University, with subsequent MD, PhD, and clinical training at Johns Hopkins University, Johns Hopkins Hospital, and the National Cancer Institute.
Jonathan B. Lloyd Jones, ACA, MBA
Chief Financial Officer and Vice President, Corporate Development
Jonathan B. Lloyd Jones has more than 25 years of experience leading teams in product licensing, finance, and operations. Most recently Jonathan was VP of Finance at TransMolecular where he was a key contributor to TransMolecular's strategic planning and chief architect of its corporate messaging. Previously Jonathan was with Genzyme from 1996 to 2006, where he was Senior Director of Corporate Development. There he developed Genzyme's Opportunity Analysis Process for conducting due diligence and valuation exercises, and headed Genzyme's Business Analysis, Valuation & Modeling, and Commercial Assessment groups. Prior to Genzyme, Jonathan headed all banking and financial operations at The Royal Bank of Scotland (Nassau) Ltd., part of The Royal Bank of Scotland Group. Jonathan holds an M.B.A. with a dual major in strategic management and finance from The Wharton School of the University of Pennsylvania and is a UK Chartered Accountant.
James E. Goldschmidt, PhD
Vice President, Commercial Development
Dr. Goldschmidt has over 25 years of experience in oncology and specialty products development, commercialization and business development. Before joining TetraLogic Pharmaceuticals, Dr. Goldschmidt was Executive Director of New Oncology Products and Business Development at Johnson & Johnson. Prior to J&J, he held several senior positions at Wyeth Pharmaceuticals, including Chair of the Oncology Therapeutic Area Leadership Team and Executive Director of Oncology New Business. Jim started his career at SmithKline Beecham, now GlaxoSmithKline plc, where he held Product Director positions in US Marketing and Global Strategic Product Development for oncology and specialty pharmaceutical products. Jim received his Ph.D. in pharmacology from Temple University School of Medicine.
Martin A. Graham, PhD
Vice President, Development
Dr. Graham was a founder of PKPD Incorporated, a clinical pharmacology research and development organization. Prior to founding PKPD Inc., he had been Vice President of Development at Gemin X Biotechnologies, a Canadian-based oncology drug discovery and development company. Martin has also served as Director of Pharmacokinetics at Centocor Inc. and Associate Director of Pharmacokinetics at Sanofi-Synthelabo Pharmaceuticals, where he was responsible for the pharmacokinetics and clinical pharmacology sections of the MAA and NDA submissions for Oxaliplatin, Urate Oxidase, Mitguazone and Alfuzosin. Martin received his Ph.D. in pharmacology at the Institute of Cancer Research at the Royal Marsden Hospital, University of London, England and conducted post-doctoral research at the Beatson Institute, University of Glasgow, Scotland where he headed the pharmacokinetics group.
Stephen M. Condon, PhD
Vice President, Chemistry
Dr. Condon is Vice President for Chemistry at TetraLogic Pharmaceuticals. Prior to joining TetraLogic Pharmaceuticals in 2004, Dr. Condon was a Group Leader in medicinal chemistry at ViroPharma Corporation where he was involved in the discovery and development of inhibitors of hepatitis C NS5B RNA-dependent RNA polymerase. From 1995-2000, Dr. Condon was a member of the medicinal chemistry group at Rhône-Poulenc Rorer where his work led to the discovery of number of highly active anabolic agents for the treatment of post-menopausal osteoporosis and the elucidation of the bioactive conformation of human parathyroid hormone. In 1994, Dr. Condon received his doctoral degree with Professor Amos B. Smith III at the University of Pennsylvania after completing the total syntheses of rapamycin and demethoxyrapamycin.